Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 74
Selected: 0
NCT IDTitle
NCT00953576Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
NCT06046040TmPSMA-02 in mCRPC
NCT01379742Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT03492424Ablative Therapy in the Management of Prostate Cancer
NCT02300324The Bioavailability Of Sulforaphane From Broccoli Soups Study (BOBS)
NCT03761160Mobile Health App to Mitigate the Metabolic Effects of Androgen Deprivation Therapy
NCT06126731Combination Study of Antibiotics With Enzalutamide (PROMIZE)
NCT03358563Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer
NCT05355727PROSAIC-DS Study (PROState AI in Cancer - Decision Support)
NCT05766371Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
NCT01961713Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy
NCT02135484Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases
NCT02025413Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method
NCT07050433Correlate Biomarkers for the SYNERGY- 201 Study
NCT04824937Telaglenastat + Talazoparib In Prostate Cancer
NCT02470936Web-based Lifestyle Trial Among Men With Prostate Cancer: Prostate 8
NCT03007732Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
NCT02985021Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
NCT03031821Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome
NCT00156884A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
NCT00744549Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance
NCT03276572Phase I Trial of 225Ac-J591 in Patients With mCRPC
NCT02445976Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.
NCT04090528pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
NCT03532217Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
NCT02677376Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC
NCT0471672568Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
NCT03440554Non-contrast MR Imaging for Whole Body Cancer Detection and Characterization
NCT05702619Hypoxia-driven Prostate Cancer Genomics (HYPROGEN)
NCT06171139Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
NCT04430192Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
NCT05765500RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
NCT05113537Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
NCT03644303Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.
NCT03957252Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer
NCT00651222Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy
NCT05041504A Web-based Peer Navigation Program for Men With Prostate Cancer
NCT05150236EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC
NCT06616597Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
NCT05445609Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT01417182Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer
NCT06040125Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
NCT05078151Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer
NCT05435495Mechanisms of Resistance to PSMA Radioligand Therapy
NCT02735252PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
NCT02499835Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
NCT04457232Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation
NCT07002320Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
NCT01990196Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
NCT01950143Effect of Sulforaphane on Prostate CAncer PrEvention